Verastem, Inc. (VSTM) Stock
NMQ · VSTM
7.45
Fundamentals
Market cap
$700.96M
Price / Earnings ratio
-3.5x
Price / Sales ratio
8.1x
Price / Book ratio
14.1x
Return on assets
-92.0%
Ex-Dividend date
N/A
Last payment date
N/A
Dividend amount
$0.00
Dividend yield
0.00%
Debt / Equity ratio
N/A
Recent news

Business Wire
Verastem Oncology Announces Late-Breaking Oral Presentation of RAMP 201 Low-Grade Serous Ovarian Cancer Molecular Profiling and Tumor Biomarker Analysis at IGCS 2026 Annual Global Meeting
NeutralVSTMSeptember 24, 2026
Business WireNeutral
Verastem Oncology Announces Late-Breaking Oral Presentation of RAMP 201 Low-Grade Serous Ovarian Cancer Molecular Profiling and Tumor Biomarker Analysis at IGCS 2026 Annual Global Meeting
VSTM

MarketBeat
Verastem Highlights Ovarian Cancer Launch, KRAS G12D Program at H.C. Wainwright
NeutralVSTMSeptember 22, 2026
MarketBeatNeutral
Verastem Highlights Ovarian Cancer Launch, KRAS G12D Program at H.C. Wainwright
VSTM

Zacks Investment Research
Verastem Stock Skyrockets 121% in 3 Months: Here Is Why
NeutralVSTMSeptember 8, 2026
Zacks Investment ResearchNeutral
Verastem Stock Skyrockets 121% in 3 Months: Here Is Why
VSTM

Business Wire
Verastem Oncology to Unveil New Clinical Data Highlighting the Best-in-Class Potential of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, Across Pancreatic, Lung, and Colorectal Cancers
NeutralVSTMSeptember 8, 2026
Business WireNeutral
Verastem Oncology to Unveil New Clinical Data Highlighting the Best-in-Class Potential of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, Across Pancreatic, Lung, and Colorectal Cancers
VSTM
Technicals
OscillatorsStrong Sell5 Indicators
Moving AveragesBuy12 Indicators
Analyst Ratings
Strong Sell0
Sell0
Neutral0
Buy6
Strong Buy0
Financials
Performance
Revenue
Net income
Net margin %
2025
37M24M12M0
Debt & Balance Sheet
Total assets
Total liabilities
2025
296M195M98M0
Revenue to Profit
2025$30.9M
Revenue$0.0
Cost of revenue$0.0
Gross profit$0.0
Operating expenses$-209.5M
Net incomeEarnings
EPS forecast
Actual EPS
$-0.46
Q4FY25
$-0.57
Q1FY26
The market is expecting earnings per share of -$0.57 for this quarter. The company has not yet shared when it is announcing earnings.
% positive news of 10 articles
published over the past 14 days
Latest news

Business Wire
Verastem Oncology Announces Late-Breaking Oral Presentation of RAMP 201 Low-Grade Serous Ovarian Cancer Molecular Profiling and Tumor Biomarker Analysis at IGCS 2026 Annual Global Meeting
NeutralVSTMSeptember 24, 2026
Business WireNeutral
Verastem Oncology Announces Late-Breaking Oral Presentation of RAMP 201 Low-Grade Serous Ovarian Cancer Molecular Profiling and Tumor Biomarker Analysis at IGCS 2026 Annual Global Meeting
VSTM

MarketBeat
Verastem Highlights Ovarian Cancer Launch, KRAS G12D Program at H.C. Wainwright
NeutralVSTMSeptember 22, 2026
MarketBeatNeutral
Verastem Highlights Ovarian Cancer Launch, KRAS G12D Program at H.C. Wainwright
VSTM

Zacks Investment Research
Verastem Stock Skyrockets 121% in 3 Months: Here Is Why
NeutralVSTMSeptember 8, 2026
Zacks Investment ResearchNeutral
Verastem Stock Skyrockets 121% in 3 Months: Here Is Why
VSTM

Business Wire
Verastem Oncology to Unveil New Clinical Data Highlighting the Best-in-Class Potential of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, Across Pancreatic, Lung, and Colorectal Cancers
NeutralVSTMSeptember 8, 2026
Business WireNeutral
Verastem Oncology to Unveil New Clinical Data Highlighting the Best-in-Class Potential of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, Across Pancreatic, Lung, and Colorectal Cancers
VSTM

Business Wire
Verastem Oncology to Participate in Upcoming September Investor Conferences
NeutralVSTMSeptember 2, 2026
Business WireNeutral
Verastem Oncology to Participate in Upcoming September Investor Conferences
VSTM

MarketBeat
Verastem Q2 Earnings Call Highlights
NeutralVSTMAugust 7, 2026
MarketBeatNeutral
Verastem Q2 Earnings Call Highlights
VSTM

Zacks Investment Research
Verastem (VSTM) Reports Q2 Loss, Beats Revenue Estimates
NeutralVSTMAugust 6, 2026
Zacks Investment ResearchNeutral
Verastem (VSTM) Reports Q2 Loss, Beats Revenue Estimates
VSTM

Business Wire
Verastem Oncology Reports Second Quarter 2026 Financial Results and Highlights Recent Business Updates
NeutralVSTMAugust 6, 2026
Business WireNeutral
Verastem Oncology Reports Second Quarter 2026 Financial Results and Highlights Recent Business Updates
VSTM

Business Wire
Verastem Oncology Doses First Patient in TARGET-D 203 Phase 2 Registration-Directed Trial of VS-7375 Oral KRAS G12D (ON/OFF) Inhibitor for KRAS G12D-Mutated Metastatic Colorectal Cancer
NeutralVSTMJuly 28, 2026
Business WireNeutral
Verastem Oncology Doses First Patient in TARGET-D 203 Phase 2 Registration-Directed Trial of VS-7375 Oral KRAS G12D (ON/OFF) Inhibitor for KRAS G12D-Mutated Metastatic Colorectal Cancer
VSTM

Business Wire
Verastem Oncology to Report Second Quarter 2026 Financial Results on August 6, 2026
NeutralVSTMJuly 23, 2026
Business WireNeutral
Verastem Oncology to Report Second Quarter 2026 Financial Results on August 6, 2026
VSTM
About Verastem, Inc.
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.
SectorHealthcare
IndustryBiotechnology
Employees102
CEOMr. Daniel W. Paterson
IPO DateJan 27, 2012
HeadquartersNeedham, MA
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Daniel W. Paterson | President, CEO & Director | 1961 |
| Mr. Daniel Calkins | Chief Financial Officer | 1988 |
| Dr. Michael Glen Kauffman M.D., Ph.D. | President of Development & Director | 1963 |
| Dr. Robert A. Weinberg Ph.D. | Co-Founder & Chair of Scientific Advisory Board | — |
| Dr. Michelle Detwiler M.D., Ph.D. | Co-Founder | 1976 |
| Ms. Lori Horvat | Executive Vice President of Portfolio Strategy & Operations | — |
| Dr. Jonathan Pachter Ph.D. | Chief Scientific Officer | 1958 |
| Ms. Julissa Viana | Vice President of Corporate Communications & Investor Relations | — |
| Mr. Mark J. Wanda | Senior VP of Legal & Chief Compliance Officer | — |
| Ms. Cathy Carew | Chief Organizational Effectiveness Officer | — |
Fundamentals
Valuation
Market cap$700.96M
Price-to-sales ratio8.07
Price-to-book value14.13
Price-earnings ratio-3.50
Return on Equity-486.00%
Return on Sales-389.00%
Return on Assets-92.00%
PEG ratio-1.89
Earnings Per Share
Earnings Per Share$-2.36
Income Statement
Average volume2,358,102
EBITDA$-191.72M
1 year high (52w)$10.82
1 year low (52w)$3.43
Dividend
Ex dividend dateN/A
Dividend amount$0.00
Dividend yield0.00%
Last payment dateN/A
Dividend yield (TTM)N/A
Next earnings reportN/A
Solvency
Debt-to-equity ratioN/A
Technicals
OscillatorsStrong Sell5 Indicators
Moving AveragesBuy12 Indicators
What the experts say
6 Wall Street Analyst Ratings
BUY
100% Buy
0% Hold
0% Sell
Target price
$15.00
Est return
94.05%
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | +1.3 | -15.9 | -1.1 | -19.6 | ||||||||
| 2022 | -27.1 | -23.6 | +17.5 | -0.7 | -11.7 | -7.2 | -5.3 | +7.4 | -26.1 | -52.0 | +5.7 | -7.5 |
| 2023 | +54.3 | -19.3 | -16.2 | +0.2 | +131.8 | -38.3 | +42.7 | -11.1 | -17.5 | -19.9 | +9.2 | +16.1 |
| 2024 | +41.6 | +1.7 | -9.4 | -14.9 | -60.3 | -24.4 | -20.0 | +2.9 | +23.6 | +33.3 | +36.2 | -6.3 |
| 2025 | -6.3 | -1.9 | +8.8 | +28.7 | +1.2 | -31.1 | +43.8 | +52.1 | -4.2 | +7.4 | +7.5 | -25.3 |
| 2026 | -15.6 | -8.5 | -8.9 | -1.6 | -25.9 | -8.8 | +41.5 | +26.9 | +1.7 |



